83 related articles for article (PubMed ID: 22830233)
1. Certolizumab pegol.
Goel N; Stephens S
MAbs; 2010; 2(2):137-47. PubMed ID: 20190560
[TBL] [Abstract][Full Text] [Related]
2. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870).
Dinesen L; Travis S
Int J Nanomedicine; 2007; 2(1):39-47. PubMed ID: 17722511
[TBL] [Abstract][Full Text] [Related]
3. Development of eosinophilic fasciitis during treatment with certolizumab pegol for ankylosing spondylitis.
Debusschere C; De Schepper S; Piette Y; Vanhaecke A; Verbist C; Smith V
Clin Exp Rheumatol; 2020; 38(4):799. PubMed ID: 32242807
[No Abstract] [Full Text] [Related]
4. Eosinophilic fasciitis induced by certolizumab pegol: association or coincidence?
Wang G; Zhuo N; Wen Z
Clin Exp Rheumatol; 2023 Sep; 41 Suppl 135(9):17. PubMed ID: 35766000
[No Abstract] [Full Text] [Related]
5. Avacincaptad Pegol Sodium.
Am J Health Syst Pharm; 2023 Dec; 80(24):1761-1762. PubMed ID: 37797160
[No Abstract] [Full Text] [Related]
6. Guselkumab in Crohn's disease: the IL-23 race continues.
Fumery M; Buisson A
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):97-98. PubMed ID: 38104570
[No Abstract] [Full Text] [Related]
7. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
8. Certolizumab (Cimzia) for Crohn's disease.
Med Lett Drugs Ther; 2008 Oct; 50(1297):81-2. PubMed ID: 18927521
[No Abstract] [Full Text] [Related]
9. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
12. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
Lazebnik LB; Kniazev OV
Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
